Amphastar Pharmaceuticals AMPH Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Geography | ||||||
| CN | $5.59M+75.4% | $3.18M-28.5% | $4.45M+61.8% | $2.75M-31.5% | $4.02M-7.4% | |
| FR | $37.07M+5.1% | $35.28M+4.1% | $33.89M+18.0% | $28.73M+10.4% | $26.03M+30.5% | |
| US | $677.87M-0.5% | $681.42M-0.5% | $684.96M-0.9% | $691.2M-1.3% | $700.61M-1.0% | |
| Non-Current Assets by Geography | ||||||
| CN | $438.66M-0.4% | $440.58M+0.5% | $438.41M+1.5% | $431.78M+3.5% | $417.22M+4.2% | |
| FR | $146.47M+0.2% | $146.14M+1.8% | $143.58M-0.1% | $143.79M+1.0% | $142.31M-1.2% | |
| US | $855.76M+3.2% | $829.02M+0.5% | $824.65M+2.4% | $805.07M-40.5% | $1.35B-29.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amphastar Pharmaceuticals break its business down?
- Amphastar Pharmaceuticals (AMPH) reports revenue by business across 2 parts — Finished Pharmaceutical Products and Pharmaceutical Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Amphastar Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amphastar Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
